Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Indiana Seed Fund III
Indianapolis, Indiana, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Indiana Seed Fund III is a $9 million early‑stage venture capital fund managed by BioCrossroads (via its for‑profit affiliate BCI) that invests in Indiana-based life sciences, health IT, diagnostics, medical device, pharmaceutical, and ag-bioscience startups.[1][2][6][7][9]
- Industry
- Investors
02
Partnerships
Eli Lilly and CompanyIndiana UniversityUniversity of Notre DameRichard M. Fairbanks FoundationBC Initiative (BCI), affiliate of BioCrossroads
Beyond the preview
Go deeper on Indiana Seed Fund III.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indiana Seed Fund III.